Patents by Inventor Ian Caley

Ian Caley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8617533
    Abstract: Viral replicon selected nucleic acid expression libraries are useful for analyzing multiple antigens associated with a parasite, pathogen or neoplasia or for preparing immunogenic compositions for generating immune responses specific for the parasite, pathogen or neoplasia. Alphavirus replicon particles representative of the nucleic acid expression library are preferred. The nucleic acid library can be a random library, or it can be prepared after a selection step, for example, by differential hybridization prior to cloning into the replicon vector.
    Type: Grant
    Filed: May 6, 2008
    Date of Patent: December 31, 2013
    Assignee: AlphaVax, Inc.
    Inventors: Jonathan F. Smith, Kurt Kamrud, Sergey Dryga, Ian Caley
  • Publication number: 20080213309
    Abstract: Viral replicon selected nucleic acid expression libraries are useful for analyzing multiple antigens associated with a parasite, pathogen or neoplasia or for preparing immunogenic compositions for generating immune responses specific for the parasite, pathogen or neoplasia. Alphavirus replicon particles representative of the nucleic acid expression library are preferred. The nucleic acid library can be a random library, or it can be prepared after a selection step, for example, by differential hybridization prior to cloning into the replicon vector.
    Type: Application
    Filed: May 6, 2008
    Publication date: September 4, 2008
    Applicant: ALPHVAX, INC.
    Inventors: Jonathan F. Smith, Kurt Kamrud, Sergey Dryga, Ian Caley
  • Publication number: 20060177819
    Abstract: The present invention provides compositions useful in and methods for producing populations of infectious, replication-defective alphavirus replicon particles that contain no replication competent alphavirus particles, as determined by passage on cells in culture. The compositions include helper and replicon nucleic acid molecules that can further reduce the predicted frequency for formation of replication-competent virus and can optimize manufacturing strategies and costs.
    Type: Application
    Filed: March 16, 2006
    Publication date: August 10, 2006
    Inventors: Jonathan Smith, Kurt Kamrud, Jonathan Rayner, Sergey Dryga, Ian Caley
  • Publication number: 20050123555
    Abstract: The present invention provides methods and compositions comprising a population of alphavirus replicon particles comprising two or more isolated nucleic acids selected from 1) an isolated nucleic acid encoding an env gene product or an immunogenic fragment thereof of a human immunodeficiency virus, 2) an isolated nucleic acid encoding a gag gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the gag gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the gag gene product or the immunogenic fragment thereof and their release from a cell, and 3) an isolated nucleic acid encoding a pol gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the pol gene product or immunogenic fragment thereof is modified to inhibit protease, integrase, RNase H and/or reverse transcriptase activity, and wherein the nucleic acids are each contained within a separate alphavirus replicon particle.
    Type: Application
    Filed: August 30, 2004
    Publication date: June 9, 2005
    Inventors: Robert Olmsted, Paula Keith, Sergey Dryga, Ian Caley, Maureen Maughan, Robert Johnston, Nancy Davis, Ronald Swanstrom
  • Publication number: 20040208848
    Abstract: Viral replicon selected nucleic acid expression libraries are useful for analyzing multiple antigens associated with a parasite, pathogen or neoplasia or for preparing immunogenic compositions for generating immune responses specific for the parasite, pathogen or neoplasia. Alphavirus replicon particles representative of the nucleic acid expression library are preferred. The nucleic acid library can be a random library, or it can be prepared after a selection step, for example, by differential hybridization prior to cloning into the replicon vector.
    Type: Application
    Filed: December 12, 2003
    Publication date: October 21, 2004
    Inventors: Jonathan F. Smith, Kurt Kamrud, Sergey Dryga, Ian Caley
  • Patent number: 6783939
    Abstract: The present invention provides methods and compositions comprising a population of alphavirus replicon particles comprising two or more isolated nucleic acids selected from 1) an isolated nucleic acid encoding an env gene product or an immunogenic fragment thereof of a human immunodeficiency virus, 2) an isolated nucleic acid encoding a g&agr;g gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the g&agr;g gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the g&agr;g gene product or the immunogenic fragment thereof and their release from a cell, and 3) an isolated nucleic acid encoding a pol gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the pol gene product or immunogenic fragment thereof is modified to inhibit protease, integrase, RNase H and/or reverse transcriptase activity, and wherein the nucleic acids are each contained within a separate alphavirus replicon
    Type: Grant
    Filed: November 16, 2001
    Date of Patent: August 31, 2004
    Assignees: Alphavax, Inc., University of North Carolina at Chapel Hill
    Inventors: Robert Olmsted, Paula Keith, Sergey Dryga, Ian Caley, Maureen Maughan, Robert Johnston, Nancy Davis, Ronald Swanstrom
  • Publication number: 20020141975
    Abstract: The present invention provides methods and compositions comprising a population of alphavirus replicon particles comprising two or more isolated nucleic acids selected from 1) an isolated nucleic acid encoding an env gene product or an immunogenic fragment thereof of a human immunodeficiency virus, 2) an isolated nucleic acid encoding a gag gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the gag gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the gag gene product or the immunogenic fragment thereof and their release from a cell, and 3) an isolated nucleic acid encoding a pol gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the pol gene product or immunogenic fragment thereof is modified to inhibit protease, integrase, RNase H and/or reverse transcriptase activity, and wherein the nucleic acids are each contained within a separate alphavirus replicon particle.
    Type: Application
    Filed: November 16, 2001
    Publication date: October 3, 2002
    Applicant: AlphaVax, Inc.
    Inventors: Robert Olmsted, Paula Keith, Sergey Dryga, Ian Caley, Maureen Maughan, Robert Johnston, Nancy Davis, Ronald Swanstrom